Regeneron Pharmaceuticals (REGN) EBITDA (2009 - 2026)

Regeneron Pharmaceuticals' EBITDA history runs 18 years deep, the most recent figure standing at $642.9 million for Q1 2026.

• On a quarterly basis, EBITDA rose 8.65% year-over-year to $642.9 million in Q1 2026; TTM through Mar 2026 was $3.6 billion, a 5.27% decrease from a year earlier, with the FY2025 full-year figure at $3.6 billion, down 10.34% from the prior year.
• EBITDA fell to $642.9 million in Q1 2026 per REGN's latest filing, from $879.9 million in the prior quarter.
• Across five years, EBITDA topped out at $1.3 billion in Q1 2022 and bottomed at $591.7 million in Q1 2025.
• The 5-year median for EBITDA is $1.0 billion (2025), against an average of $999.9 million.
• Biggest YoY gain for EBITDA was 13.1% in 2022; the steepest drop was 66.84% in 2022.
• Year by year, EBITDA stood at $1.1 billion in 2022, then dropped by 15.16% to $972.9 million in 2023, then climbed by 1.78% to $990.2 million in 2024, then slipped by 11.14% to $879.9 million in 2025, then slipped by 26.93% to $642.9 million in 2026.
• Per Business Quant, the three latest REGN EBITDA figures stand at $642.9 million (Q1 2026), $879.9 million (Q4 2025), and $1.0 billion (Q3 2025).